FLGT News and Press, Fulgent Genetics Inc. From 02/12/21

Fulgent Genetics is an upstart in the genetic testing business, and it has achieved remarkable business momentum since inception. Management is (very) well aligned and has an admirable track record. COVID-19 has been a tremendous business tailwind for Fulgent, as the COVID testing...

Scientists are beginning to arrive at the notion that the fight with Covid-19 is not a short raging battle that will be over by summer 2021 but a long-term war that will be waged for many years to come, with a constant need for PPE, testing, vaccine rejiggering, specialized air filtration sol...

Fulgent Genetics (NASDAQ: FLGT) stock is up big so far in 2021. However, it's had some pretty wild swings along the way. In this Motley Fool Live video recorded on Feb. 3 , Fool.com contributors Keith Speights and Brian Orelli discuss why Fulgent Genetics stock is so vo...

Gainers: Ocugen OCGN +76%, Cassava Sciences SAVA +65%, Moleculin Biotech MBRX +47%, Artelo Biosciences (ARTL) +28%, Atossa Therapeutics (ATOS) +20%.Losers: Immunovant IMVT -39%, Dynavax Technologies (DVAX) -19%, Retractable Technolog...

The good news is that the end of the pandemic is in sight. The bad news is that it may never really be over. Even after we achieve the big goal of vaccine-induced herd immunity in the developed world, the pandemic will fester and mutate and hide out in the emerging world, continuously threate...

Are you excited about the potential of cutting-edge companies like CRISPR Therapeutics (NASDAQ: CRSP) , Fulgent Genetics (NASDAQ: FLGT) , or Invitae Corp. (NYSE: NVTA) ? You're not alone. The genetic testing market is expected to expand at a compound annual growth ra...

Twilio (NYSE: TWLO) and Fulgent Genetics (NASDAQ: FLGT) delivered returns of 228% and 317%, respectively, in 2020, even as the COVID-19 pandemic wreaked havoc on various industries and (for awhile) the market. Both businesses made some smart moves in 2020 that should continu...

It's hard to think of an industry that was more impacted by the 2020 COVID pandemic than diagnostics. The often-overlooked part of the healthcare system sprang into action, testing more than 250 million people last year in the U.S. alone. And interestingly, some testing companies performed ...

TEMPLE CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its C...

Fulgent's core genetic testing business is recovering and should improve even further due to synergies with the COVID-19 business. Many people thought COVID-19 would dissipate in 2021 as the vaccine is rolled out, but delays in administration of the vaccine mean that testing will cont...